Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer

Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models f...

Full description

Saved in:
Bibliographic Details
Published in:Annals of translational medicine 2019-10, Vol.7 (20), p.572-572
Main Authors: Berardi, Rossana, Santoni, Matteo, Rinaldi, Silvia, Bower, Marc, Tiberi, Michela, Morgese, Francesca, Caramanti, Miriam, Savini, Agnese, Ferrini, Consuelo, Torniai, Mariangela, Fiordoliva, Ilaria, Newsom-Davis, Thomas
Format: Article
Language:English
Subjects:
Original
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c323t-7c0894a650d4caf46886b03084ce195b03cef5c352b63633e79c5317f5e2c9383
cites
container_end_page 572
container_issue 20
container_start_page 572
container_title Annals of translational medicine
container_volume 7
creator Berardi, Rossana
Santoni, Matteo
Rinaldi, Silvia
Bower, Marc
Tiberi, Michela
Morgese, Francesca
Caramanti, Miriam
Savini, Agnese
Ferrini, Consuelo
Torniai, Mariangela
Fiordoliva, Ilaria
Newsom-Davis, Thomas
description Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) SII
doi_str_mv 10.21037/atm.2019.09.18
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6861803</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322741373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-7c0894a650d4caf46886b03084ce195b03cef5c352b63633e79c5317f5e2c9383</originalsourceid><addsrcrecordid>eNpVkc1vFSEUxYnR2KZ27c6wdDOvwB1mYGNiGr-SJrrQNeHx7rxiBhiBqenGv12mrU3dwE3OL4fDPYS85mwnOIPxwtawE4zrHdM7rp6RUwFMdlKBfv5kPiHnpfxkjHHBNTD2kpwAV2yUEk7Jn28Zu5qxWWGstNyWisE76kNYI3Y-TrMNwVafIs24ZCwNK9TSJadjTKU2drKupkx9pEsD7_Tfvl5Te7ix0eGBxhS7Euw8U4ftmNd4pG6T8ivyYrJzwfOH-4z8-Pjh--Xn7urrpy-X7686BwJqNzqmdG8HyQ69s1M_KDXsGTDVO-RattHhJB1IsR9gAMBROwl8nCQKp0HBGXl377us-4AH10JmO5sl-2DzrUnWm_-V6K_NMd2YQQ1tV9AM3j4Y5PRrxVJN8GX7jY2Y1mIECDH2HMYNvbhHXU6lZJwen-HM3BVn2rbNVpxh2vAt3Zun6R75fzXBX3Ptl50</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322741373</pqid></control><display><type>article</type><title>Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer</title><source>PubMed (Medline)</source><creator>Berardi, Rossana ; Santoni, Matteo ; Rinaldi, Silvia ; Bower, Marc ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Newsom-Davis, Thomas</creator><creatorcontrib>Berardi, Rossana ; Santoni, Matteo ; Rinaldi, Silvia ; Bower, Marc ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Newsom-Davis, Thomas</creatorcontrib><description>Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) SII &lt;1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses. At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P&lt;0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII &gt;1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS. Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</description><identifier>ISSN: 2305-5839</identifier><identifier>EISSN: 2305-5839</identifier><identifier>DOI: 10.21037/atm.2019.09.18</identifier><identifier>PMID: 31807553</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Annals of translational medicine, 2019-10, Vol.7 (20), p.572-572</ispartof><rights>2019 Annals of Translational Medicine. All rights reserved.</rights><rights>2019 Annals of Translational Medicine. All rights reserved. 2019 Annals of Translational Medicine.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-7c0894a650d4caf46886b03084ce195b03cef5c352b63633e79c5317f5e2c9383</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861803/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861803/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31807553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Rinaldi, Silvia</creatorcontrib><creatorcontrib>Bower, Marc</creatorcontrib><creatorcontrib>Tiberi, Michela</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Caramanti, Miriam</creatorcontrib><creatorcontrib>Savini, Agnese</creatorcontrib><creatorcontrib>Ferrini, Consuelo</creatorcontrib><creatorcontrib>Torniai, Mariangela</creatorcontrib><creatorcontrib>Fiordoliva, Ilaria</creatorcontrib><creatorcontrib>Newsom-Davis, Thomas</creatorcontrib><title>Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer</title><title>Annals of translational medicine</title><addtitle>Ann Transl Med</addtitle><description>Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) SII &lt;1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses. At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P&lt;0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII &gt;1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS. Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</description><subject>Original</subject><issn>2305-5839</issn><issn>2305-5839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkc1vFSEUxYnR2KZ27c6wdDOvwB1mYGNiGr-SJrrQNeHx7rxiBhiBqenGv12mrU3dwE3OL4fDPYS85mwnOIPxwtawE4zrHdM7rp6RUwFMdlKBfv5kPiHnpfxkjHHBNTD2kpwAV2yUEk7Jn28Zu5qxWWGstNyWisE76kNYI3Y-TrMNwVafIs24ZCwNK9TSJadjTKU2drKupkx9pEsD7_Tfvl5Te7ix0eGBxhS7Euw8U4ftmNd4pG6T8ivyYrJzwfOH-4z8-Pjh--Xn7urrpy-X7686BwJqNzqmdG8HyQ69s1M_KDXsGTDVO-RattHhJB1IsR9gAMBROwl8nCQKp0HBGXl377us-4AH10JmO5sl-2DzrUnWm_-V6K_NMd2YQQ1tV9AM3j4Y5PRrxVJN8GX7jY2Y1mIECDH2HMYNvbhHXU6lZJwen-HM3BVn2rbNVpxh2vAt3Zun6R75fzXBX3Ptl50</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Berardi, Rossana</creator><creator>Santoni, Matteo</creator><creator>Rinaldi, Silvia</creator><creator>Bower, Marc</creator><creator>Tiberi, Michela</creator><creator>Morgese, Francesca</creator><creator>Caramanti, Miriam</creator><creator>Savini, Agnese</creator><creator>Ferrini, Consuelo</creator><creator>Torniai, Mariangela</creator><creator>Fiordoliva, Ilaria</creator><creator>Newsom-Davis, Thomas</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201910</creationdate><title>Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer</title><author>Berardi, Rossana ; Santoni, Matteo ; Rinaldi, Silvia ; Bower, Marc ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Newsom-Davis, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-7c0894a650d4caf46886b03084ce195b03cef5c352b63633e79c5317f5e2c9383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Rinaldi, Silvia</creatorcontrib><creatorcontrib>Bower, Marc</creatorcontrib><creatorcontrib>Tiberi, Michela</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Caramanti, Miriam</creatorcontrib><creatorcontrib>Savini, Agnese</creatorcontrib><creatorcontrib>Ferrini, Consuelo</creatorcontrib><creatorcontrib>Torniai, Mariangela</creatorcontrib><creatorcontrib>Fiordoliva, Ilaria</creatorcontrib><creatorcontrib>Newsom-Davis, Thomas</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berardi, Rossana</au><au>Santoni, Matteo</au><au>Rinaldi, Silvia</au><au>Bower, Marc</au><au>Tiberi, Michela</au><au>Morgese, Francesca</au><au>Caramanti, Miriam</au><au>Savini, Agnese</au><au>Ferrini, Consuelo</au><au>Torniai, Mariangela</au><au>Fiordoliva, Ilaria</au><au>Newsom-Davis, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer</atitle><jtitle>Annals of translational medicine</jtitle><addtitle>Ann Transl Med</addtitle><date>2019-10</date><risdate>2019</risdate><volume>7</volume><issue>20</issue><spage>572</spage><epage>572</epage><pages>572-572</pages><issn>2305-5839</issn><eissn>2305-5839</eissn><abstract>Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) SII &lt;1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses. At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P&lt;0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII &gt;1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS. Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>31807553</pmid><doi>10.21037/atm.2019.09.18</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2305-5839
ispartof Annals of translational medicine, 2019-10, Vol.7 (20), p.572-572
issn 2305-5839
2305-5839
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6861803
source PubMed (Medline)
subjects Original
title Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A47%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-treatment%20systemic%20immune-inflammation%20represents%20a%20prognostic%20factor%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer&rft.jtitle=Annals%20of%20translational%20medicine&rft.au=Berardi,%20Rossana&rft.date=2019-10&rft.volume=7&rft.issue=20&rft.spage=572&rft.epage=572&rft.pages=572-572&rft.issn=2305-5839&rft.eissn=2305-5839&rft_id=info:doi/10.21037/atm.2019.09.18&rft_dat=%3Cproquest_pubme%3E2322741373%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c323t-7c0894a650d4caf46886b03084ce195b03cef5c352b63633e79c5317f5e2c9383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2322741373&rft_id=info:pmid/31807553&rfr_iscdi=true